title: Treatment of chronic viral hepatitis anno 1990.
abstract: Alpha-interferon has emerged as the most effective agent for the treatment of chronic hepatitis when active replication of virus B, C, or D is present. Exogenous administration of human alpha-interferon, now possible through modern large-scale production methods, is associated with suppression of virus in blood. Amelioration of liver disease occurs in 35% of patients with hepatitis B virus and in 50% with hepatitis C virus with interferon doses of 30 and 10 MU per week, respectively, for 16-26 weeks; after therapy, persistent normalization of serum alanine aminotransferase is observed in 35% and 27%, respectively. Similar results have now also been reported for chronic hepatitis D. Enhanced response rates (greater than 50%) may be obtained by prolonged intermittent interferon therapy. Combination of interferon with another 'antiviral' agent (vidarabine, acyclovir, prednisone) has not increased therapeutic efficacy. Alpha-interferon induces side effects such as fatigue, flu-like syndrome, myalgia, and changes in mood and granulocytes. Patients with decompensated cirrhosis are particularly prone to bacterial infection and disease exacerbation and should receive lower doses. Interferon, when applied skillfully, induces the highly beneficial transition of active viral replication into viral latency, thereby greatly reducing infectivity, symptoms, and activity of the liver disease. Prevention of death from liver failure or hepatocellular carcinoma is to be expected.
authors: Dept. of Internal Medicine & Hepatogastroenterology, University Hospital Dijkzigt, Rotterdam, The Netherlands.
authors: S W
authors: SW
authors: Schalm
mesh_terms: D002908:Chronic Disease; D006509:Hepatitis B / Q000628:therapy; D006526:Hepatitis C / Q000628:therapy; D003699:Hepatitis D / Q000628:therapy; D006525:Hepatitis, Viral, Human / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007370:Interferon Type I